Survivor since 2013
Carolyn, I'm all for raloxifen because it has less side effects, and does not have the drug interactions that tamoxifen does. The patient information that comes with it says that it has not been fully studied in women who have breast cancer. I think that is why it has not been FDA approved for the treatment of breast cancer - not because it is not effective - but because it has not been fully studied in women with breast cancer. It is approved for osteoporosis and for women at high risk of getting breast cancer. " Raloxifene has never been approved for use as a drug to treat bc. Sometimes it is offered to women who cannot tolerate the side effects of tamoxifen, but this is not done routinely". The study that has been done on r and t is the STAR study. It has studied the reduction of risk to women at high risk of getting bc. But not as a treatment for women with bc. Long term results have shown both to be effective : t reduces risk in high risk women by 50% , while r reduces by 38% . Updated results do show both effective for invasive and noninvasive.